<code id='F32493247C'></code><style id='F32493247C'></style>
    • <acronym id='F32493247C'></acronym>
      <center id='F32493247C'><center id='F32493247C'><tfoot id='F32493247C'></tfoot></center><abbr id='F32493247C'><dir id='F32493247C'><tfoot id='F32493247C'></tfoot><noframes id='F32493247C'>

    • <optgroup id='F32493247C'><strike id='F32493247C'><sup id='F32493247C'></sup></strike><code id='F32493247C'></code></optgroup>
        1. <b id='F32493247C'><label id='F32493247C'><select id='F32493247C'><dt id='F32493247C'><span id='F32493247C'></span></dt></select></label></b><u id='F32493247C'></u>
          <i id='F32493247C'><strike id='F32493247C'><tt id='F32493247C'><pre id='F32493247C'></pre></tt></strike></i>

          knowledge

          knowledge

          author:hotspot    Page View:7225
          Adam's take main illustration
          Molly Ferguson/STAT

          This week, an encouraging turnaround for Ocular Therapeutix, a chat with Alnylam’s CEO defending changes to the HELIOS-B study and talking up its hypertension treatment, and quick takes on Amylyx and obesity stocks.

          A Worst CEO gets some much-needed help

          For most of last year, Ocular Therapeutix CEO Antony Mattessich promised shareholders that he was close to nailing down a lucrative pharma partnership that would pay for late-stage clinical trials of the company’s treatments for degenerative eye diseases. The deal never happened. I heard from many Ocular investors who were frustrated and angry about Mattesich’s poor job performance. He ended up earning a spot last year on my worst biopharma CEO list. It was an easy pick.

          advertisement

          On Thursday, Ocular announced a meaningful “leadership update.” Mattessich is still the CEO, but let’s just say the company’s board decided to surround him with new executives and retinal experts with proven track records of getting stuff done.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Anesthesiologist group: stop taking Ozempic before surgery
          Anesthesiologist group: stop taking Ozempic before surgery

          EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

          read more
          New company forms to vet health AI models, root out weaknesses
          New company forms to vet health AI models, root out weaknesses

          AdobeThemarketforartificialintelligenceinhealthcareisaboutastransparentasabrickwall.Newtoolsachievei

          read more
          At least 13 dead in Texas as scorching temps continue
          At least 13 dead in Texas as scorching temps continue

          1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

          read more

          Calls for Trump's election interference trial to be televised part of long debate

          8:40MediamembersprepareforthearrivalofformerPresidentDonaldTrump,whoisfacingfederalchargesinconnecti